OncoMatch/Clinical Trials/NCT06624475
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Is NCT06624475 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Relatlimab plus Nivolumab for basal cell carcinoma.
Treatment: Nivolumab · Relatlimab plus Nivolumab — This is a Phase 2 clinical trial with a 2:1 randomization comparing neoadjuvant Nivolumab + Relatlimab (Opdualag) vs neoadjuvant Nivolumab in patients with resectable high risk basal cell carcinoma (HR BCC)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational agent
Is currently receiving any other investigational agents.
Cannot have received: investigational product/device
Has participated in a study of an investigational product and received study treatment or used an investigational device within 4 weeks of the first dose of study treatment.
Cannot have received: radiation therapy
Exception: Participants must have recovered (i.e., Grade ≤1 or at baseline) from radiation related toxicities prior to first study treatment.
Radiation therapy within 2 weeks prior to first study treatment.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/microliter; Platelets ≥ 100,000/microliter
Kidney function
Creatinine clearance > 30 mL/min (Cockcroft Gault formula)
Liver function
Total bilirubin >1.5 x institutional upper limit of normal (except Gilbert Syndrome <3.0xULN); AST ≤ 3 x ULN; ALT ≤ 3 x ULN
Adequate bone marrow function: Absolute neutrophil count ≥ 1,500/microliter; Platelets ≥ 100,000/microliter. Adequate hepatic function: Total bilirubin >1.5 x institutional upper limit of normal (except participants with Gilbert Syndrome who must have a total bilirubin level of <3.0xULN); AST ≤ 3 x institutional upper limit of normal; ALT ≤ 3 x institutional upper limit of normal. Adequate renal function: Creatinine clearance > 30 mL/min (using the Cockcroft Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Irvine · Irvine, California
- University of California, San Diego Moores Cancer Center · La Jolla, California
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06624475 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify